Leiden

• MAD Ended recruitment
  2024-516379-34-00 6 2024-08-02 Myopia
• A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants with Previously Untreated High- … Ended recruitment
  2023-510178-15-00 5 2024-07-31 High-risk Large B-cell Lymphoma
• Comparison of targeted radiotherapy with and without short-term hormonal treatment (6 months) Ended recruitment
  2024-511252-41-00 5 2024-07-30 Patients with biochemical recurrence after primary treatment of prosta
• A study to learn the effects of ripretinib (study drug) on how midazolam behaves in the body of people with advanced gastrointestinal stroma … Ended recruitment
  2022-501477-40-00 3 2024-06-25 Advanced Gastrointestinal Stromal Tumor
• TGF‐β And PDL‐1 inhibition with Bintrafusp alfa in Esophageal Squamous Cell carcinoma combined with chemoradiation TheRapY (TAPESTRY) Ended recruitment
  2023-503312-32-00 4 2024-06-24 Esophageal squamous cell carcinoma
• (Treatments to shrink tumors before surgery, radiation or other forms of nondrug therapy) to use the investigational drug (Darovasertib) in … Ended recruitment
  2023-506683-14-00 4 2024-06-14 Uveal Melanoma
• A study evaluating the safety and efficacy of GLPG5101 (19CP02) in subjects with non-Hodgkin lymphoma Ended recruitment
  2022-502661-23-00 7 2024-06-11 Relapsed/refractory B-cell non-Hodgkin lymphoma
• A Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascu … Ended recruitment
  2022-502781-24-01 5 2024-06-05 ASCVD - Atherosclerotic Cardiovascular Disease
• Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change i … Ended recruitment
  2023-506906-38-00 5 2024-05-23 Follicular Lymphoma
• MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer Ended recruitment
  2023-504816-14-00 5 2024-03-08 Endometrial cancer
• A Phase 1/2, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Intrav … Ended recruitment
  2023-506737-30-00 7 2024-03-08 Duchenne Muscular Dystrophy
• A clinical Study to Evaluate Metreleptin Treatment in Subjects with Partial Lipodystrophy over 12-Month Timeframe Ended recruitment
  2022-501799-24-00 5 2024-03-07 partial lipodystrophy
• A study of sigvotatug vedotin versus docetaxel in previously treated non-small cell lung cancer (Be6A Lung-01) Ended recruitment
  2023-503827-25-01 5 2024-02-16 Non-Small Cell Lung Cancer (NSCLC)
• Effects of BBP-418 (ribitol) in Patients with LGMD2I Ended recruitment
  2023-503379-33-01 5 2024-02-12 Limb Girdle Muscular Dystrophy 2I/R9
• A Phase III study to investigate two initial administrations of COMP360 in treatment-resistant depression Ended recruitment
  2023-505268-12-00 5 2024-02-09 Treatment-resistant depression
• Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304) Ended recruitment
  2022-502669-14-00 5 2023-12-18 Small cell lung cancer (SCLC)
• Public Title: Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Participants with M … Ended recruitment
  2022-502975-45-00 5 2023-12-12 Metastatic leiomyosarcoma
• A phase I/II open label, multicenter study evaluating the feasibility, safety and efficacy of point-of-care manufactured antiBCMA CAR T cell … Ended recruitment
  2022-500782-27-00 7 2023-11-14 relapsed/refractory Multiple Myeloma
• Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib in G12C NSCLC Patients (RAMP203) Ended recruitment
  2023-505107-24-00 9 2023-11-14 Non-small cell lung cancer
• A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with N … Ended recruitment
  2022-500802-16-00 5 2023-11-01 Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung
• A Phase 2b, Double-Blind, Randomized Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntingt … Ended recruitment
  2023-504628-24-00 4 2023-10-31 Huntington's Disease
• A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Fluad and Fluad … Ended recruitment
  2022-503004-24-00 5 2023-10-20 Influenza virus
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants with Systemic Lupus Er … Ended recruitment
  2022-502632-39-00 1 2023-10-11 Systemic Lupus Erythematosus (SLE)
• Long-Term Follow-Up of TX200-TR101 (STEADFAST Long Term) Ended recruitment
  2024-512580-31-00 5 2023-07-21 Kidney Transplant Rejection

Showing 265–288 of 450 trials